华润三九旗下创新药益气清肺颗粒在京东健康线上首发

Group 1 - The core viewpoint of the news is the launch of 999 Yiqi Qingfei Granules, the first domestic drug for respiratory infection recovery, developed by China Resources Sanjiu in collaboration with academician Zhang Boli and his team [1] - The drug aims to address symptoms such as fatigue, shortness of breath, and dry cough that occur during the recovery phase of respiratory infections, which have been traditionally overlooked in treatment [1] - The formulation is based on classic traditional Chinese medicine prescriptions and has undergone rigorous clinical trials to validate its safety and efficacy [1] Group 2 - JD Health is leveraging its super pharmaceutical supply chain and omnichannel service capabilities to meet the growing demand for effective and safe medications during the flu season [2] - The company has partnered with multiple pharmaceutical firms to launch new drugs targeting flu and respiratory symptoms, enhancing the accessibility and efficiency of quality pharmaceutical products [2] - JD Health positions itself as the "first station for new specialty drug launches," facilitating precise delivery of healthcare products to users [2]